Allogeneic Myeloma GM-CSF Vaccine With Lenalidomide in Multiple Myeloma Patients in Complete or Near Complete Remission
Clinical trial NCT03376477 · TERMINATED
Trial details
- NCT number
- NCT03376477
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2019-09-23
- Primary completion
- 2024-01-02
- Enrollment
- 24
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.